30 / 40
Evidencia en primera línea frente a
Antiangiogénico: Estudio PEAK
Rivera F, et al. Int J Colorectal Dis 2017;32:1179
-
90.
*From stratified Cox model;
†
As assessed by RECIST (for ORR n = 81 for
the WT
RAS
bevacizumab group);
‡
Defined as the odds of having an
objective response in the panitumumab + mFOLFOX6 arm relative to the
odds in the bevacizumab + mFOLFOX6 arm;
¥
Stratified exact test.
WT RAS
Panitumumab
+ mFOLFOX6
(n = 88)
Bevacizumab
+ mFOLFOX6
(n = 82)
Median PFS, months
(95% CI)
12.8
(10.7‒15.1)
10.1
(9.0‒12.7)
Hazard ratio (95% CI)
0.68 (0.48‒0.96)
P-value*
0.029
Median OS, months
(95% CI)
36.9
(27.9‒46.1)
28.9
(23.3‒32.0)
Hazard ratio (95% CI)
0.76 (0.53‒1.11)
P-value*
0.15
ORR,
†
%
(95% CI)
65
(54‒75)
60
(49‒71)
Odds ratio
‡
(95% CI)
1.12 (0.56‒2.22)
P-value
¥
0.86